Skip to main content
×
Home
    • Aa
    • Aa

Homocysteine-lowering therapy does not lead to reduction in cardiovascular outcomes in chronic kidney disease patients: a meta-analysis of randomised, controlled trials

  • Yu Pan (a1), Li Li Guo (a1), Ling Ling Cai (a1), Xiao Juan Zhu (a1), Jin Lian Shu (a1), Xiao Li Liu (a1) and Hui Min Jin (a1)...
Abstract

The efficacy of homocysteine (Hcy)-lowering therapy in reducing the risk of CVD among patients with chronic kidney disease (CKD) remains controversial. We performed a meta-analysis to determine whether pooling the data from the few small randomised, controlled trials that address this topic would improve the statistical power of the analysis and resolve some of the inconsistencies in the results. Randomised, controlled clinical trials (RCT) were identified from MEDLINE, EMBASE, www.clinicaltrials.gov, the Cochrane Controlled Clinical Trials Register Database and Nephrology Filters. Independent extraction of articles was performed using predefined data fields. The primary outcome was relative risk (RR) of CVD, CHD, stroke and all-cause mortality for the pooled trials. A stratified analysis was planned, assessing the RR for cardiovascular events between the patients on and not on dialysis. Overall, ten studies met the inclusion criteria. The estimated RR were not significantly different for any outcomes, including CHD (RR 1·00, 95 % CI 0·75, 1·31, P = 0·97), CVD (RR 0·94, 95 % CI 0·84, 1·05, P = 0·30), stroke (RR 0·83, 95 % CI 0·57, 1·19, P = 0·31) and all-cause mortality (RR 1·00, 95 % CI 0·92, 1·09, P = 0·98). In the stratified analysis, the estimated RR were not significantly different for cardiovascular events regardless of dialysis or in combination with vitamin B therapy or the degree of reduction in Hcy levels. Our meta-analysis of RCT supports the conclusion that Hcy-lowering therapy was not associated with a significant decrease in the risk for CVD events, stroke and all-cause mortality among patients with CKD.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Homocysteine-lowering therapy does not lead to reduction in cardiovascular outcomes in chronic kidney disease patients: a meta-analysis of randomised, controlled trials
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your Dropbox account. Find out more about sending content to Dropbox.

      Homocysteine-lowering therapy does not lead to reduction in cardiovascular outcomes in chronic kidney disease patients: a meta-analysis of randomised, controlled trials
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your Google Drive account. Find out more about sending content to Google Drive.

      Homocysteine-lowering therapy does not lead to reduction in cardiovascular outcomes in chronic kidney disease patients: a meta-analysis of randomised, controlled trials
      Available formats
      ×
Copyright
Corresponding author
*Corresponding author: H. M. Jin, fax +86 21 56691662, email hmjgli@yahoo.com.cn
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

1 AK Cheung , MJ Sarnak , G Yan , (2004) Cardiac diseases in maintenance hemodialysis patients: results of the HEMO study. Kidney Int 65, 23802389.

2 MJ Sarnak , AS Levey , AC Schoolwerth , (2003) Kidney disease as a risk factor for the development of cardiovascular disease. Circulation 108, 21542169.

3 AS Go , GM Chertow & D Fan (2004) Chronic kidney disease and the risk of death, cardiovascular events, and hospitalization. N Engl J Med 351, 12961305.

4 JW Eikelboom , EM Lonn , J Genest , (1999) Homocysteine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med 131, 363375.

5 B Bayes , MC Pastor , J Bonal , (2005) New cardiovascular risk factors in patients with chronic kidney disease: role of folic acid treatment. Kidney Int Suppl S39S43.

6 F Wollesen , B Brattstrom , H Refsum , (1999) Plasma total homocysteine and cystein in relation to glomerular filtration rate. Kidney Int 55, 10281035.

7 F Mallamaci , C Zoccali , G Tripepi , (2002) Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney Int 61, 609614.

10 LA Bazzano , K Reynolds , KN Holder , (2006) Effect of folic acid supplementation on the risk of cardiovascular diseases. JAMA 296, 27202726.

11 ME Suliman , B Lindholm , P Barany , (2007) Homocysteine-lowering is not a primary target for cardiovascular disease prevention in chronic kidney disease patients. Semin Dial 20, 523529.

12 S Zoungas , BP McGrath , P Branley , (2006) Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure – a multicenter, randomized, controlled trial. J Am Coll Cardiol 47, 11081116.

13 EM Wrone , JM Homberger , JL Zehnder , (2004) Randomized trial of folic acid for prevention of cardiovascular events in end stage renal disease. J Am Soc Nephrol 15, 420426.

14 M Righetti , P Serbelloni , S Milani , (2006) Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients. Blood Purif 24, 379386.

15 X Qin , Y Huo , CB Langman , (2011) Folic acid therapy and cardiovascular disease in ESRD or advanced chronic kidney disease: a meta-analysis. Clin J Am Soc Nephrol 6, 482488.

17 AC Vianna , AJ Mocelin , T Matsuo , (2007) Uremic hyperhomocysteinemia: a randomized trial of folate treatment for the prevention of cardiovascular events. Hemodial Int 11, 210216.

19 JFE Mann , P Sheridan , MJ McQueen , (2008) Homocysteine lowering with folic acid and B vitamins in people with chronic kidney disease – results of the renal Hope-2 study. Nephrol Dial Transplant 23, 645653.

20 RL Jamison , P Hartigan , JS Kaufman , (2007) Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA 298, 11631170.

21 AA House , M Eliasziw , DC Cattran , (2010) Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA 303, 16031609.

22 J Heinz , S Kropf , U Domröse , (2010) B-vitamins and the risk of total mortality and cardiovascular disease in end-stage renal disease results of a randomized controlled trial. Circulation 121, 14321438.

23 ME Widlansky , N Gokce , JF Keaney , (2003) The clinical implications of endothelial dysfunction. J Am Coll Cardiol 42, 11491160.

24 V Schachinger , MB Britten & AM Zeiher (2000) Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 101, 18991906.

25 S Tatematsu , S Wakino , T Kanda , (2007) Role of nitric oxide producing and degrading pathways in coronary endothelial dysfunction in chronic kidney disease. J Am Soc Nephrol 18, 741749.

27 C van Guldener , MJ Janssen , J Lambert , (1998) No change in impaired endothelial function after long-term folic acid therapy of hyperhomocysteinaemia in hemodialysis patients. Nephrol Dial Transplant 13, 106112.

28 M Arnadottir , V Gudnason & B Hultberg (2000) Treatment with different doses of folic acid in hemodialysis patients: effects on folate distribution and aminothiol concentrations. Nephrol Dial Transplant 15, 524528.

29 CJ Boushey , SA Beresford , GS Omenn , (1995) A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 274, 10491057.

30 R Tremblay , A Bonnardeaux , D Geadah , (2000) Hyperhomocysteinemia in hemodialysis patients: effects of 12-month supplementation with hydrosoluble vitamins. Kidney Int 58, 851858.

31 S Billion , B Tribout , E Cadet , (2002) Hyperhomocysteinaemia, folate and vitamin B12 in unsupplemented haemodialysis patients: effect of oral therapy with folic acid and vitamin B12. Nephrol Dial Transplant 17, 455461.

32 M Födinger , C Mannhalter , G Wölfl , (1997) Mutation (677 C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients. Kidney Int 52, 517523.

33 AA House , GA Wells , JG Donnelly , (2000) Randomized trial of high-flux vs low-flux haemodialysis: effects on homocysteine and lipids. Nephrol Dial Transplant 15, 10291034.

34 S Biasioli , R Schiavon , L Petrosino , (1998) Dialysis kinetics of homocysteine and reactive oxygen species. ASAIO J 44, M423M432.

35 F Galli , S Benedetti , U Buoncristiani , (2003) The effect of PMMA-based protein-leaking dialyzers on plasma homocysteine levels. Kidney Int 64, 748755.

36 DW Mudge , R Rogers , P Hollett , (2005) Randomized trial of FX high flux vs. standard high flux dialysis for homocysteine clearance. Nephrol Dial Transplant 20, 21782185.

38 MR Mehrabi , K Huber , N Serbecic , (2002) Enrichment of homocysteine in coronary arteries of patients with coronary artery disease. Thromb Res 107, 189196.

39 AR Jadad , RA Moore , D Carroll , (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17, 112.

40 M Ebbing , KH Bønaa , O Nygård , (2009) Cancer incidence and mortality after treatment with folic acid and vitamin B12. JAMA 302, 21192126.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

British Journal of Nutrition
  • ISSN: 0007-1145
  • EISSN: 1475-2662
  • URL: /core/journals/british-journal-of-nutrition
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords:

Metrics

Full text views

Total number of HTML views: 6
Total number of PDF views: 77 *
Loading metrics...

Abstract views

Total abstract views: 136 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 24th June 2017. This data will be updated every 24 hours.